NASDAQ: EKSOEkso Bionics Holdings Inc Stock
$1.28+0.10 (+8.47%)
Updated Apr 25, 2024
EKSO Price
$1.28
Fair Value Price
$2.16
Market Cap
$22.92M
52 Week Low
$0.62
52 Week High
$3.13
P/E
-1.16x
P/B
1.82x
P/S
1.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.28M
Earnings
-$15.20M
Gross Margin
49.7%
Operating Margin
-81.49%
Profit Margin
-83.1%
Debt to Equity
1.29
Operating Cash Flow
-$12M
Beta
0.63
Next Earnings
Apr 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
EKSO Overview
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EKSO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EKSO ($1.28) is undervalued by 40.63% relative to our estimate of its Fair Value price of $2.16 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EKSO ($1.28) is significantly undervalued by 40.63% relative to our estimate of its Fair Value price of $2.16 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EKSO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EKSO due diligence checks available for Premium users.
Be the first to know about important EKSO news, forecast changes, insider trades & much more!
EKSO News
Valuation
EKSO fair value
Fair Value of EKSO stock based on Discounted Cash Flow (DCF)
Price
$1.28
Fair Value
$2.16
Undervalued by
40.63%
EKSO ($1.28) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EKSO ($1.28) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EKSO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EKSO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.16x
Industry
47.92x
Market
40.97x
EKSO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.82x
Industry
3.49x
EKSO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EKSO's financial health
Profit margin
Revenue
$4.8M
Net Income
-$3.2M
Profit Margin
-66.3%
EKSO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EKSO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$28.9M
Liabilities
$16.3M
Debt to equity
1.29
EKSO's short-term assets ($20.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EKSO's short-term assets ($20.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EKSO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EKSO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$43.0k
Financing
$0.0
EKSO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EKSO vs Medical Stocks
Ekso Bionics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.